Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia

Published: Monday, Jul 08, 2019
Matthew S. Davids, MD

Matthew S. Davids, MD, MMSc
OncLive®: How would you characterize the significance of the ALLIANCE, ECOG E1912, and iLLUMINATE trials within the broader treatment spectrum for chronic lymphocytic leukemia (CLL)?

Davids: At a high-level, it was an exciting opportunity, because we had 3 large randomized trials reading out at the same time, and all 3 looked different CLL patient populations. ECOG19121 for younger patients, ALLIANCE2 for more typical older patients, and iLLUMINATE,3 with an older, frailer population.

The comparative arms for the trials were appropriate standards of care: for the young patients it was FCR [fludarabine, cyclophosphamide, and rituximab], for the middle group of patients it was bendamustine (BR), and then for the older, frailer patients it was chlorambucil with obinutuzumab.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication